Biologics, Small Molecules, Devices
Total Trials
3
As Lead Sponsor
2
As Collaborator
1
Total Enrollment
1,658
NCT05531968
Treatment of Moderate to Severe Glabellar Lines (BMI2006)
Phase: Phase 3
Role: Lead Sponsor
Start: Feb 9, 2021
Completion: Sep 17, 2021
NCT05922813
Evaluate the Safety and Tolerability of a Single-dose Administration of BMI2004 Inj.
Phase: Phase 1
Start: Jun 30, 2022
Completion: Apr 12, 2023
NCT07204457
Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old
Phase: Phase 2/3
Role: Collaborator
Start: Oct 31, 2025
Completion: Jun 30, 2027
Loading map...